[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: Effects of aging, in vivo blockade, and anti-Aβ antibody treatment

Neurobiology of Disease

Volumn 43, Issue 3, 2011, Pages 565-575

  Teng, Edmond ^a,b   Kepe, Vladimir ^a   Frautschy, Sally A ^a,b   Liu, Jie ^a   Satyamurthy, Nagichettiar ^a   Yang, Fusheng ^a,b   Chen, Ping Ping ^a,b   Cole, Graham B ^a   Jones, Mychica R ^a,b   Huang, Sung Cheng ^a   Flood, Dorothy G ^c   Trusko, Stephen P ^c   Small, Gary W ^a   Cole, Gregory M ^a,b   Barrio, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c Cephalon Inc   (United States)

Author keywords

F 18 FDDNP; Amyloid; Immunotherapy; Naproxen; Positron emission tomography; Transgenic rat

Indexed keywords

2 [1 [6 [(2 FLUOROETHYL)(METHYL)AMINO]-2-NAPHTHYL]ETHYLIDENE] MALONONITRILE F 18; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6E10; NAPROXEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG BINDING; DRUG TARGETING; FRONTAL CORTEX; HIPPOCAMPUS; IN VIVO STUDY; MOLECULAR PROBE; NON INVASIVE MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN SYNTHESIS; RAT; TRANSGENIC RAT;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, BLOCKING; BINDING, COMPETITIVE; DISEASE MODELS, ANIMAL; FLUORINE RADIOISOTOPES; HUMANS; NAPROXEN; NITRILES; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC;

EID: 79960245809     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.05.003     Document Type: Article

References (55)

1. Agdeppa E.D., et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J. Neurosci. 2001, 21:RC189.
2. Agdeppa E.D., et al. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malono nitrile. Neuroscience 2003, 117:723-730.
3. Bacskai B.J., et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch. Neurol. 2007, 64:431-434.
4. Barrio J.R., et al. 3-(2'-[18F]fluoroethyl)spiperone: in vivo biochemical and kinetic characterization in rodents, nonhuman primates, and humans. J. Cereb. Blood Flow Metab. 1989, 9:830-839.
5. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
6. Braskie M.N., et al. Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. Neurobiol. Aging. 2010, 31:1669-1678.
7. Bussiere T., et al. Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am. J. Pathol. 2004, 165:987-995.
8. Cairns N.J., et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch. Neurol. 2009, 66:1557-1562.
9. Calon F., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43:633-645.
10. Chow P.L., et al. Attenuation correction for small animal PET tomographs. Phys. Med. Biol. 2005, 50:1837-1850.
11. Chow P.L., et al. A method of image registration for small animal, multi-modality imaging. Phys. Med. Biol. 2006, 51:379-390.
12. Cole G.M., Frautschy S.A. Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol. Disord. Drug Targets 2010, 9:140-148.
13. Cole G.B., et al. Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6222-6227.
14. Farde L., et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:3863-3867.
15. Flood D.G., et al. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition. Neurobiol. Aging 2009, 30:1078-1090.
16. Ikonomovic M.D., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
17. Jack C.R., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
18. Kalback W., et al. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 2002, 41:922-928.
19. Klunk W.E., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 2004, 55:306-319.
20. Klunk W.E., et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 2005, 25:10598-10606.
21. Kuntner C., et al. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol. Imaging Biol. 2009, 11:236-240.
22. Kuo Y.M., et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 2001, 276:12991-12998.
23. Lacan G., et al. Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2256-2266.
24. Lim G.P., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 2000, 20:5709-5714.
25. Lim G.P., et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001, 21:8370-8377.
26. Liu J., et al. High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononi trile ([18F]FDDNP) ready for animal or human administration. Mol. Imaging Biol. 2007, 9:6-16.
27. Liu L., et al. A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Neurobiol. Dis. 2008, 31:46-57.
28. Loening A.M., Gambhir S.S. AMIDE: a free software tool for multimodality medical image analysis. Mol. Imaging 2003, 2:131-137.
29. Luurtsema G., et al. Peripheral metabolism of [(18)F]FDDNP and cerebral uptake of its labelled metabolites. Nucl. Med. Biol. 2008, 35:869-874.
30. Maeda J., et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007, 27:10957-10968.
31. Mathis C.A., et al. Species-dependent metabolism of the amyloid imaging agent [C-11]PIB. J. Nucl. Med. 2004, 45(Suppl):114P.
32. Oddo S., et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332.
33. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2005, Academic Press, San Diego.
34. Phelps M.E., Barrio J.R. Correlation of brain amyloid with "aerobic glycolysis": a question of assumptions?. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17459-17460.
35. Protas H.D., et al. FDDNP binding using MR derived cortical surface maps. NeuroImage 2010, 49:240-248.
36. Rinne J.O., et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9:363-372.
37. Rowe C.C., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
38. Rowe C.C., et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008, 7:129-135.
39. Shoghi-Jadid K., et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 2002, 10:24-35.
40. Small G.W., et al. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 2006, 355:2652-2663.
41. Suckow C., et al. Multimodality rodent imaging chambers for use under barrier conditions with gas anesthesia. Mol. Imaging Biol. 2009, 11:100-106.
42. Tai Y.C., et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J. Nucl. Med. 2005, 46:455-463.
43. Thakker D.R., et al. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4501-4506.
44. Thie J.A. Understanding the standardized uptake value, its methods, and implications for usage. J. Nucl. Med. 2004, 45:1431-1434.
45. Toga A.W., et al. A 3D digital map of rat brain. Brain Res. Bull. 1995, 38:77-85.
46. Tolboom N., et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J. Nucl. Med. 2009, 50:191-197.
47. Tolboom N., et al. Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J. Neurol. Neurosurg. Psychiatry 2010, 81:882-884.
48. Toyama H., et al. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:593-600.
49. Tucker S.M., et al. Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2008, 67:30-40.
50. Vandenberghe R., et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 2010, 68:319-329.
51. Verhoeff N.P., et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry 2004, 12:584-595.
52. Wilcock D.M., et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 2003, 23:3745-3751.
53. Wong D.F., et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 2010, 51:913-920.
54. Yang F., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280:5892-5901.
55. Yaqub M., et al. Evaluation of tracer kinetic models for analysis of [18F]FDDNP studies. Mol. Imaging Biol. 2009, 11:322-333.